TITLE

Adjuvant Intraportal Venous Chemotherapy for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombi Following Hepatectomy Plus Portal Thrombectomy

AUTHOR(S)
Li-Jian Liang; Wen-Jie Hu; Xiao-Yu Yin; Qi Zhou; Bao-Gang Peng; Dong-Ming Li; Ming-De Lu
PUB. DATE
April 2008
SOURCE
World Journal of Surgery;Apr2008, Vol. 32 Issue 4, p627
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The aim of this study was to evaluate the clinical value of adjuvant chemobiotherapy via portal vein for patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombi (PVTT) following hepatectomy plus thrombectomy. Eighty-six HCC patients with tumor thrombi in the portal trunk and/or the first-order branch were divided into groups A ( n = 33) and B ( n = 53). Patients in group A were treated with hepatectomy plus portal thrombectomy in combination with postoperative adjuvant chemobiotherapy administered via portal vein. The chemobiotherapy regimen consisted of 5-FU, adriamycin, cisplatin, and IFNα. Patients in Group B were subjected to hepatectomy plus thrombectomy alone. Survival rates of the two groups were compared and prognostic factors were identified using Cox proportional hazards model. Group A had a significantly longer median tumor-free survival time and median survival time compared with group B, i.e., 5.1 vs. 2.5 months ( p = 0.017) and 11.5 vs. 6.2 months ( p = 0.007), respectively. One-, two-, and three-year tumor-free survival rates were remarkably higher in group A than in group B, i.e., 18.4% vs. 8.4%, 13.8% vs. 4.2%, and 9.2% vs. 4.2%, respectively. One-, two-, and three-year survival rates were markedly greater in group A than in group B, i.e., 46.8% vs. 23.4%, 14.4% vs. 5.8%, and 9.6% vs. 5.8%, respectively. Multivariate analysis using the Cox proportional hazards model revealed that adjuvant chemobiotherapy, pathologic grading, and tumor size were independent prognostic factors for survival time ( p = 0.000, 0.001, and 0.013, respectively), and chemobiotherapy and pathologic grading were independent prognostic factors for tumor-free survival time ( p = 0.002 and 0.003, respectively). Surgical resection combined with adjuvant chemobiotherapy via portal vein is an effective and safe treatment modality for hepatocellular carcinoma with major portal vein thrombus.
ACCESSION #
31295178

 

Related Articles

  • Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Ju Hyun Shim; Joong-Won Park; Byung Ho Nam; Woo Jin Lee; Chang-Min Kim // Cancer Chemotherapy & Pharmacology;Feb2009, Vol. 63 Issue 3, p459 

    The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC). We retrospectively analyzed the data of 178 assessable among 195 consecutive HCC patients ineligible for curative therapy who were treated with XP at the National...

  • The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Kogure, Takayuki; Ueno, Yoshiyuki; Iwasaki, Takao; Shimosegawa, Toru // Cancer Chemotherapy & Pharmacology;Apr2004, Vol. 53 Issue 4, p296 

    Purpose. Several clinical trials in human neoplasms have demonstrated the effectiveness of combination therapy with 5-fluorouracil (FUra), cisplatin (CDDP), and leucovorin (LV). Thymidylate synthase (TS), the target enzyme of FUra, and dihydropyrimidine dehydrogenase (DPD), the rate-limiting...

  • Docetaxel in hepatic impairment. Kolesar, J.M. // Journal of Oncology Pharmacy Practice;Jun2000, Vol. 6 Issue 2, p43 

    Purpose. The primary objective of this paper is to provide a brief overview of docetaxel pharmacokinetics, pharmacodynamics, indications, and drug interactions, concentrating on their relationship with docetaxel use in patients with hepatic impairment. Data Sources. The literature was reviewed...

  • A Hepatocellular Carcinoma of Massive Arterioportal Shunts Without Tumor Stain Treated with CDDP Two--Route Chemotherapy--A Case Report j. Matama, Sumio; Ishii, Kohdoh; Satoh, Kiyotaka; Sohtome, Shigeru; Sasaki, Kenichi // Angiology;Sep1990 Part 1, Vol. 41 Issue 9, p737 

    Massive arterioportal shunts without tumor vessels or tumor stain are sometimes encountered in advanced cases of liver cirrhosis. Massive arterioportal shunts without tumor stain that responded well to intensive chemotherapy with cis-diamminedichloroplatinum II are reported.

  • Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases. Uka, Kiminori; Aikata, Hiroshi; Takaki, Shintaro; Kawaoka, Tomokazu; Saneto, Hiromi; Miki, Daiki; Takahashi, Shoichi; Toyota, Naoyuki; Ito, Katsuhide; Chayama, Kazuaki; Rodrigo, Luis; Shimada, Mitsuo; Hanazaki, Kazuhiro // World Journal of Gastroenterology;4/28/2008, Vol. 14 Issue 16, p2602 

    The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC). Systemic gemcitabine chemotherapy seems effective in many cancers. We report the results of combination therapy with systemic gemcitabine, intra-arterial...

  • Repeat treatment for recurrent hepatocellular carcinoma: is it validated? Kishi, Yoji; Saiura, Akio; Yamamoto, Junji; Koga, Rintaro; Seki, Makoto; Morimura, Ryo; Yoshioka, Ryuji; Kokudo, Norihiro; Yamaguchi, Toshiharu // Langenbeck's Archives of Surgery;Oct2011, Vol. 396 Issue 7, p1093 

    Purpose: Hepatocellular carcinoma (HCC) usually recurs repeatedly and locoregional treatment is attempted unless liver function has deteriorated. This study was aimed to evaluate the effect of repeated treatment on patient prognosis. Methods: The HCC recurrence pattern and types of treatment for...

  • Chemotherapy options show good disease-free rate. Williams, Samten // Dermatology Times;Nov2000, Vol. 21 Issue 11, p38 

    Highlights the results of Phase II clinical trials using tamoxifen and cisplatin in the treatment of melanoma patients. Implications for dermatology practice; Nausea and vomiting side effects; Concern of the researchers about the patients in the Phase II trial for whom tumors have returned.

  • Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: an approach to improve the therapeutic index of highly toxic chemotherapy drugs.  // Journal of Translational Medicine;2011, Vol. 9 Issue 1, p152 

    The article discusses a study which evaluated the capability of electrochemotherapy (ECT) to allow the use of cisplatin despite its high toxicity in a spontaneous feline model of soft tissue sarcoma. The study concluded that ECT is a safe and effective therapy for solid tumors and its use may be...

  • Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Youlyouz-Marfak, I.; Gachard, N.; Le Clorennec, C.; Najjar, I.; Baran-Marszak, F.; Reminieras, L.; May, E.; Bornkamm, G. W.; Fagard, R.; Feuillard, J. // Cell Death & Differentiation;Feb2008, Vol. 15 Issue 2, p376 

    Chemotherapeutic drugs such as fludarabine*, doxorubicin or cisplatin are very potent activators of the anti-oncogene p53. Convergent studies suggest that p53 and STAT1 (signal transducer and activator of transcription 1) cooperate in the induction of cell death. We show that these drugs are...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics